DE69904297T2 - Neue verwendung von ropivacain zur schmerzbehandlung - Google Patents
Neue verwendung von ropivacain zur schmerzbehandlungInfo
- Publication number
- DE69904297T2 DE69904297T2 DE69904297T DE69904297T DE69904297T2 DE 69904297 T2 DE69904297 T2 DE 69904297T2 DE 69904297 T DE69904297 T DE 69904297T DE 69904297 T DE69904297 T DE 69904297T DE 69904297 T2 DE69904297 T2 DE 69904297T2
- Authority
- DE
- Germany
- Prior art keywords
- pain
- ropivacaine
- tender
- myofascial
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 52
- 230000036407 pain Effects 0.000 title claims abstract description 51
- 238000011282 treatment Methods 0.000 title claims abstract description 10
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims abstract description 23
- 229960001549 ropivacaine Drugs 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 8
- 208000000491 Tendinopathy Diseases 0.000 claims abstract description 6
- 206010043255 Tendonitis Diseases 0.000 claims abstract description 6
- 201000004415 tendinitis Diseases 0.000 claims abstract description 6
- 238000007918 intramuscular administration Methods 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 9
- 150000004682 monohydrates Chemical class 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000004283 incisor Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 208000000029 referred pain Diseases 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002646 transcutaneous electrical nerve stimulation Methods 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000028752 abnormal posture Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001352 masseter muscle Anatomy 0.000 description 1
- 210000003784 masticatory muscle Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229940029571 naropin Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960001813 ropivacaine hydrochloride Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000013363 skeletal muscle disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 210000001738 temporomandibular joint Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Adornments (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9800139A SE9800139D0 (sv) | 1998-01-21 | 1998-01-21 | New use |
| PCT/SE1999/000012 WO1999037301A1 (en) | 1998-01-21 | 1999-01-11 | New use for pain management |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69904297D1 DE69904297D1 (de) | 2003-01-16 |
| DE69904297T2 true DE69904297T2 (de) | 2003-08-21 |
Family
ID=20409917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69904297T Expired - Lifetime DE69904297T2 (de) | 1998-01-21 | 1999-01-11 | Neue verwendung von ropivacain zur schmerzbehandlung |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6395291B1 (https=) |
| EP (1) | EP1054671B1 (https=) |
| JP (1) | JP4456754B2 (https=) |
| AT (1) | ATE228840T1 (https=) |
| AU (1) | AU2444399A (https=) |
| DE (1) | DE69904297T2 (https=) |
| DK (1) | DK1054671T3 (https=) |
| ES (1) | ES2189386T3 (https=) |
| PT (1) | PT1054671E (https=) |
| SE (1) | SE9800139D0 (https=) |
| WO (1) | WO1999037301A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200611217A (en) * | 2005-12-06 | 2006-04-01 | Shin Hwa Biotech Co Ltd | Human model for indexing nerve paths (locus) having corresponding relations and method for indexing |
| US8920843B2 (en) * | 2007-11-07 | 2014-12-30 | Svip5 Llc | Slow release of organic salts of local anesthetics for pain relief |
| US10111850B2 (en) * | 2015-12-01 | 2018-10-30 | Samuel Wilson | Ester and cholinesterase inhibitor in long-acting nerve block |
| CA2898933A1 (en) * | 2014-07-30 | 2016-01-30 | Grigory Karmy | Method for relieving chronic pain |
| US10751249B2 (en) * | 2017-11-26 | 2020-08-25 | Johnson Athletic Advantage LLC | Trigger point dry needling in motion and method of use |
| BE1026845B1 (nl) | 2018-12-07 | 2020-07-08 | Fagron Compounding Services Nv | Samenstelling voor gebruik in lokale infiltratie analgesie (LIA) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0151110B1 (en) | 1983-08-01 | 1989-03-01 | Astra Läkemedel Aktiebolag | L-n-n-propylpipecolic acid-2,6-xylidide and method for preparing the same |
| SE451840B (sv) | 1986-01-03 | 1987-11-02 | Astra Laekemedel Ab | Optiskt rent monohydrat av s-(-)-1-propyl-2',6'-pipekoloxylididhydroklorid, sett att framstella denna och farmaceutiska beredningar for lokalbedovning |
| SE9401174D0 (sv) | 1994-04-07 | 1994-04-07 | Astra Ab | New combination |
| ATE219674T1 (de) | 1997-03-13 | 2002-07-15 | James N Campbell | Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika |
-
1998
- 1998-01-21 SE SE9800139A patent/SE9800139D0/xx unknown
-
1999
- 1999-01-11 US US09/254,382 patent/US6395291B1/en not_active Expired - Lifetime
- 1999-01-11 ES ES99903972T patent/ES2189386T3/es not_active Expired - Lifetime
- 1999-01-11 DE DE69904297T patent/DE69904297T2/de not_active Expired - Lifetime
- 1999-01-11 JP JP2000528283A patent/JP4456754B2/ja not_active Expired - Lifetime
- 1999-01-11 AU AU24443/99A patent/AU2444399A/en not_active Abandoned
- 1999-01-11 PT PT99903972T patent/PT1054671E/pt unknown
- 1999-01-11 EP EP99903972A patent/EP1054671B1/en not_active Expired - Lifetime
- 1999-01-11 DK DK99903972T patent/DK1054671T3/da active
- 1999-01-11 AT AT99903972T patent/ATE228840T1/de active
- 1999-01-11 WO PCT/SE1999/000012 patent/WO1999037301A1/en not_active Ceased
-
2002
- 2002-04-24 US US10/128,664 patent/US6620423B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1054671B1 (en) | 2002-12-04 |
| DK1054671T3 (da) | 2003-02-24 |
| JP4456754B2 (ja) | 2010-04-28 |
| WO1999037301A1 (en) | 1999-07-29 |
| ATE228840T1 (de) | 2002-12-15 |
| US6395291B1 (en) | 2002-05-28 |
| PT1054671E (pt) | 2003-03-31 |
| US6620423B2 (en) | 2003-09-16 |
| EP1054671A1 (en) | 2000-11-29 |
| US20020156101A1 (en) | 2002-10-24 |
| SE9800139D0 (sv) | 1998-01-21 |
| AU2444399A (en) | 1999-08-09 |
| JP2002501021A (ja) | 2002-01-15 |
| ES2189386T3 (es) | 2003-07-01 |
| DE69904297D1 (de) | 2003-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Moore et al. | The anesthetic efficacy of 4 percent articaine 1: 200,000 epinephrine: two controlled clinical trials | |
| DE69429536T2 (de) | Analgetisches Mittel und dessen Verwendung | |
| Munsat | Therapy of myotonia; A double‐blind evaluation of diphenylhydantoin, procainamide, and placebo | |
| DE3247062C2 (https=) | ||
| DE60118430T2 (de) | Behandlung von gastrointestinalen stromatumoren | |
| Cline et al. | Analgesia and effectiveness of levobupivacaine compared with ropivacaine in patients undergoing an axillary brachial plexus block | |
| DE69814394T2 (de) | Verwendung von levobupivacain | |
| DE69432905T2 (de) | Verwendung von ketoconazol und verwandten substanzen in medikamenten für die behandlung des typ ii-diabetes | |
| Ernberg et al. | Ropivacaine for dental anesthesia: a dose-finding study | |
| RU2095060C1 (ru) | Композиция, обладающая аналгетической или противовоспалительной активностью, способ аналгезии или лечения аллергических заболеваний | |
| EP2323645A1 (de) | Verwendung niedrig-dosierter lokalanästhetika oder derivate davon zur therapie chronischer schmerzen, insbesondere migräne | |
| Bayer et al. | Trigeminal neuralgia: an overview | |
| Shetty et al. | Comparison of anesthetic efficacy between lidocaine with and without magnesium sulfate USP 50% for inferior alveolar nerve blocks in patients with symptomatic irreversible pulpitis | |
| DE2823174A1 (de) | Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose | |
| DE69904297T2 (de) | Neue verwendung von ropivacain zur schmerzbehandlung | |
| DE69419854T2 (de) | Arzneimittelzusammensetzung zur Prophylaxe und Behandlung vorzeitigen Samenergusses | |
| DE69628743T2 (de) | Levobupivacain und dessen verwendung als anästhetikum bei schwangeren frauen | |
| DE69433898T2 (de) | Verwendung von alpha-rezeptorantagonisten zur behandlung chronischer muskelschmerzen | |
| DE69907220T2 (de) | Verwendung von substanz p antagonisten zur behandlung des chronischen ermüdungssyndroms und/oder der fibromyalgie | |
| Casale et al. | Reduction of spastic hypertonia in patients with spinal cord injury: a double-blind comparison of intravenous orphenadrine citrate and placebo | |
| Everett | A comparison of depth of anesthesia and toxicity of two and four per cent procaine hydrochloride solution | |
| DE3789173T2 (de) | Verwendung von Ketamin zur Herstellung von Arzneimitteln zur Prävention oder Linderung der Effekte von Schlaganfall bei einer Person mit erhöhtem Risiko für Schlaganfall. | |
| Kayacan et al. | Temporary neurologic complication of spinal ropivacaine in an obstetric patient | |
| Katti et al. | Comparison of Analgesic Efficacy of Nalbuphine and Fentanyl as Adjuvants to Intrathecal Hyperbaric Bupivacaine in Patients undergoing Lower Limb Orthopaedic Surgeries: Randomised Clinical Trial. | |
| Waisbren et al. | Hypersensitivity to meperidine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |